273 related articles for article (PubMed ID: 36631359)
1. Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice.
Jang Y; Cho H; Chun J; Park K; Nowakowska A; Kim J; Lee H; Lee C; Han Y; Lee HJ; Shin HY; Kim YB
Vaccine; 2023 Feb; 41(6):1223-1231. PubMed ID: 36631359
[TBL] [Abstract][Full Text] [Related]
2. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2021; 12():824728. PubMed ID: 35154086
[TBL] [Abstract][Full Text] [Related]
3. Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2.
Cho H; Jang Y; Park KH; Choi H; Nowakowska A; Lee HJ; Kim M; Kang MH; Kim JH; Shin HY; Oh YK; Kim YB
NPJ Vaccines; 2021 Mar; 6(1):37. PubMed ID: 33741992
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
5. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
Elife; 2022 Aug; 11():. PubMed ID: 36004719
[TBL] [Abstract][Full Text] [Related]
6. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
7. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X
Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227
[TBL] [Abstract][Full Text] [Related]
8. A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells.
Appelberg S; Ahlén G; Yan J; Nikouyan N; Weber S; Larsson O; Höglund U; Aleman S; Weber F; Perlhamre E; Apro J; Gidlund EK; Tuvesson O; Salati S; Cadossi M; Tegel H; Hober S; Frelin L; Mirazimi A; Sällberg M
EMBO Mol Med; 2022 Oct; 14(10):e15821. PubMed ID: 35986481
[TBL] [Abstract][Full Text] [Related]
9. Comparative Biodistribution Study of Baculoviral and Adenoviral Vector Vaccines against SARS-CoV-2.
Lee HD; Chun J; Kim S; Aleksandra N; Lee C; Yoon D; Lee HJ; Kim YB
J Microbiol Biotechnol; 2024 Jan; 34(1):185-191. PubMed ID: 37830223
[TBL] [Abstract][Full Text] [Related]
10. Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
Lee KS; Rader NA; Miller-Stump OA; Cooper M; Wong TY; Shahrier Amin M; Barbier M; Bevere JR; Ernst RK; Heath Damron F
Vaccine; 2023 Jul; 41(34):5003-5017. PubMed ID: 37407405
[TBL] [Abstract][Full Text] [Related]
11. Intramuscular administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infection.
Kim DH; Lee J; Youk S; Jeong JH; Lee DY; Ju HS; Youn HN; Kim JC; Park SB; Park JE; Kim JY; Kim TH; Lee SH; Lee H; Mouhamed Abdallah Amal Abdal L; Lee DH; Park PG; Hong KJ; Song CS
Vaccine; 2023 Jul; 41(33):4787-4797. PubMed ID: 37355454
[TBL] [Abstract][Full Text] [Related]
12. Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants.
Honda-Okubo Y; Bowen R; Barker M; Bielefeldt-Ohmann H; Petrovsky N
Vaccine; 2023 Nov; 41(48):7116-7128. PubMed ID: 37863669
[TBL] [Abstract][Full Text] [Related]
13. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
14. Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice.
Cai JP; Luo C; Wang K; Cao H; Chen LL; Zhang X; Han Y; Yin F; Zhang AJ; Chu H; Yuan S; Kok KH; To KK; Chen H; Chen Z; Jin DY; Yuen KY; Chan JF
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992395
[TBL] [Abstract][Full Text] [Related]
15. Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice.
González-Domínguez I; Martínez JL; Slamanig S; Lemus N; Liu Y; Lai TY; Carreño JM; Singh G; Singh G; Schotsaert M; Mena I; McCroskery S; Coughlan L; Krammer F; García-Sastre A; Palese P; Sun W
Microbiol Spectr; 2022 Jun; 10(3):e0153822. PubMed ID: 35658571
[TBL] [Abstract][Full Text] [Related]
16. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
17. Inactivated whole virion vaccine protects K18-hACE2 Tg mice against the Omicron SARS-CoV-2 variant via cross-reactive T cells and nonneutralizing antibody responses.
Kruglov AA; Bondareva MA; Gogoleva VS; Semin IK; Astrakhantseva IV; Zvartsev R; Lunin AS; Apolokhov VD; Shustova EY; Volok VP; Ustyugov AA; Ishmukhametov AA; Nedospasov SA; Kozlovskaya LI; Drutskaya MS
Eur J Immunol; 2024 Mar; 54(3):e2350664. PubMed ID: 38088236
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection.
Richardson JR; Götz R; Mayr V; Lohse MJ; Holthoff HP; Ungerer M
PLoS One; 2022; 17(4):e0266701. PubMed ID: 35468147
[TBL] [Abstract][Full Text] [Related]
19. Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs.
Wang B; Xu J; Wu S; Zhang Z; Zhao Z; Zhang J; Fu L; Zai X; Wang Y; Zhang G; Chen Z; Chen Y; Sun H; Song X; Zhang J; Zhu L; Hou L; Chen W
Signal Transduct Target Ther; 2022 Jul; 7(1):257. PubMed ID: 35906201
[TBL] [Abstract][Full Text] [Related]
20. Inactivated SARS-CoV-2 Vaccine Shows Cross-Protection against Bat SARS-Related Coronaviruses in Human ACE2 Transgenic Mice.
Liu MQ; Jiang RD; Guo J; Chen Y; Yang DS; Wang X; Lin HF; Li A; Li B; Hu B; Wang ZJ; Yang XL; Shi ZL
J Virol; 2022 Apr; 96(8):e0016922. PubMed ID: 35343762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
